News

A recent study found no significant differences in accuracy between methods for detecting detecting anti-HPA antibodies responsible for FNAIT.

An investigational drug developed by Rallybio to prevent FNAIT produced positive results in a phase 1 clinical trial.

A recent analysis highlighted the need for additional data on the causes and mechanisms of platelet transfusion refractoriness.

Neonatal fragment crystallizable receptor (FcRn) inhibitors could significantly decrease complications associated with FNAIT, recent studies show.

Results from the phase 1 clinical trial of RLYB212, an experimental therapy intended for FNAIT prevention, were recently published.

A new study to compare treatment with nipocalimab versus IVIG in pregnant people at risk of FNAIT will be enrolling patients soon.

A new registry of human platelet antigen (HPA)–typed blood donors may help treat fetal and neonatal alloimmune thrombocytopenia (FNAIT) in Greece.

A case report described a wrongful diagnosis of FNAIT that could have been prevented if HPA genotyping had been performed sooner.

According to a recent poster presentation, women with FNAIT reported negative effects on their emotional and physical health.

In a recent study, mothers affected by FNAIT reported their diagnosis had a significant negative effect on their well-being.